Ignite Creation Date:
2024-05-06 @ 3:07 PM
Last Modification Date:
2024-10-26 @ 1:43 PM
Study NCT ID:
NCT04521153
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2021-04-27
First Post:
2020-08-18
Brief Title:
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
Sponsor:
Shanghai Zhongshan Hospital
Organization:
Shanghai Zhongshan Hospital
Organization Data
Organization:
Shanghai Zhongshan Hospital
Class:
OTHER
Study ID:
ZS-ZJ-SK-2020
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Shanghai Zhongshan Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None